Developmental Research Program

发展研究计划

• 批准号: 10208781
• 负责人: Steven R Lentz
• 金额: $ 15.38万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-11 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10208781
• 关键词: Area; Award; Basic Science; Cancer Center; Clinic; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Development; Developmental Therapeutics Program; Discipline; Environment; Fostering; Funding; Generations; Goals; Grant; Human; Immunology; Incidence; Iowa; Laboratories; Lead; Lymphoma; Malignant Neoplasms; Morbidity - disease rate; Patient Care; Patients; Peer Review; Program Research Project Grants; Publications; Research; Research Personnel; Research Project Grants; Research Support; Resources; Scientist; Specialized Program of Research Excellence; Techniques; Testing; Translating; Translational Research; Tumor Biology; Universities; Work; base; clinically relevant; high risk; innovation; mortality; population based; programs; sound

ABSTRACT: Developmental Research Program (DRP). The goal of the University of Iowa / Mayo Clinic Lymphoma SPORE (SPORE) Developmental Research Program (DRP) is to support innovative, scientifically sound projects that investigate questions pertinent to translational lymphoma research. This program continued to be successful with support over the past 5 years going to 15 developmental research projects. Five of these projects received a second year of funding. Four of the DRP awards directly contributed to the development of the full Projects proposed in this renewal. An additional award led to an inter-SPORE trial in the renewal. In the next funding period, the DRP will provide up to $50,000 for one year ($25,000 from SPORE funds and $25,000 from institutional resources) to each of four projects each year with the possibility of a second year of support based on progress and promise. High risk/high payoff innovative concepts are encouraged. It is anticipated that support of DRP will continue to result in the generation of new hypotheses that will be tested in SPORE-sponsored research or through peer reviewed external grant support. The long- term goal of the SPORE program is to translate the findings generated by developmental projects into a reduction in the incidence and mortality rates of lymphoma. The Specific Aims of the DRP are to 1. Encourage innovative laboratory and translationally relevant clinical studies in lymphoma 2. Foster extensive collaboration between basic science, clinical and population-based disciplines in translational research in lymphoma 3. Encourage investigators to evaluate the potential of applying their research findings to translational research in lymphoma 4. Generate new hypotheses to be tested both inside and outside the SPORE in clinical trials that may lead to significant improvements in care of patients with lymphoma

摘要：发展研究计划（DRP）。爱荷华大学/梅奥诊所的目标 淋巴瘤 SPORE (SPORE) 发展研究计划 (DRP) 旨在支持创新、科学 研究与转化淋巴瘤研究相关问题的健全项目。这个节目 在过去 5 年里，我们对 15 个开发研究项目的支持继续取得成功。 其中五个项目获得了第二年的资助。其中四项 DRP 奖项直接贡献于 开发本次更新中提议的完整项目。另一项奖励导致了 SPORE 间试验 更新。在下一个资助期内，DRP 将提供一年最多 50,000 美元（SPORE 提供 25,000 美元） 资金和 25,000 美元的机构资源）每年向四个项目中的每一个项目提供 基于进展和承诺的第二年支持。高风险/高回报的创新概念是 鼓励。预计 DRP 的支持将继续导致新假设的产生 这将在 SPORE 资助的研究中或通过同行评审的外部资助支持进行测试。长- SPORE 计划的长期目标是将开发项目产生的发现转化为 降低淋巴瘤的发病率和死亡率。 DRP 的具体目标是 1. 鼓励淋巴瘤的创新实验室和转化相关临床研究 2. 促进基础科学、临床和人口学科之间的广泛合作 淋巴瘤的转化研究 3. 鼓励研究人员评估将其研究成果应用于转化的潜力 淋巴瘤研究 4. 产生新的假设，并在 SPORE 内部和外部的临床试验中进行测试，这些假设可能 显着改善淋巴瘤患者的护理